Israeli Startup ExoProTher Develops Promising Protein-Based Cancer Treatment

ExoProTher, an Israeli biotech startup, has introduced a groundbreaking protein-based cancer treatment with the potential to revolutionize cancer therapy. This innovative treatment targets mutated cells while sparing healthy ones, offering the prospect of replacing traditional, more damaging chemotherapy.

Co-founders of ExoProTher spoke with Israeli innovation news site No Camels, highlighting the treatment’s unique approach. By harnessing the power of a p53 protein, which has long been recognized for its tumor-fighting capabilities, the startup has achieved remarkable success in treating various cancers, including colon, brain, lung, and ovarian cancers.

The key breakthrough came from an unexpected source: chicken cells. These cells share similarities with human cells but possess a crucial advantage. They can distinguish between damaged and healthy DNA, prompting the damaged cells to undergo apoptosis (cell death) and preventing the formation of tumors. This precision sets the treatment apart from chemotherapy, which inadvertently damages healthy cells, leading to side effects like hair loss, nausea, anemia, and cognitive impairment.

ExoProTher’s novel approach offers broad applicability, potentially benefiting individuals with diverse cancer types. The treatment can be administered through injections or inhalation, enabling large-scale production and affordability.